| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors |
Trial sites expanded: 21 -> 28 locations |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
Trial completed |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Primary completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Completion moved earlier: 2026-07 -> 2026-05-23 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07631871 An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in… | Metastatic HER2-positive Breast Cancer | Recruiting |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care… | Biliary Tract Cancer | Recruiting |
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | Recruiting |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in… | Gastric Neoplasms | Active, Not Recruiting |
| Phase 2 | |||
| NCT07176312 | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT07405476 | Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in… | Colon Carcinoma | Recruiting |
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in… | HER2-positive Breast Cancer | Recruiting |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Breast Neoplasms | Recruiting |
| NCT05035836 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients… | Breast Cancer | Recruiting |
| NCT06043427 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer | Recruiting |
| NCT07290985 | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal… | Gastroesophageal Adenocarcinoma | Not Yet Recruiting |
| NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One… | Neoplasms | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in… | Metastatic Breast Cancer | Recruiting |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive… | HER 2 Positive Advanced Breast Cancer | Not Yet Recruiting |